<DOC>
	<DOCNO>NCT00245011</DOCNO>
	<brief_summary>RATIONALE : Radioactive drug , samarium Sm 153 lexidronam pentasodium , may carry radiation directly tumor cell harm normal cell . A peripheral stem cell transplant may able replace blood-forming cell destroy chemotherapy samarium Sm 153 lexidronam pentasodium . Radiation therapy use high-energy x-ray kill tumor cell . Giving samarium Sm 153 lexidronam pentasodium together peripheral stem cell transplant radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give samarium Sm 153 lexidronam pentasodium together autologous stem cell transplant radiation therapy work treat patient recurrent refractory , metastatic , unresectable osteosarcoma .</brief_summary>
	<brief_title>Samarium Sm 153 Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine clinical response patient recurrent refractory , metastatic , unresectable osteosarcoma treat high-dose samarium Sm 153 lexidronam pentasodium ( ^153Sm-EDTMP ) autologous peripheral blood stem cell transplantation follow external-beam radiotherapy . - Correlate amount radiation deliver tumor low-dose ^153Sm-EDTMP high-dose ^153Sm-EDTMP patient treat regimen . Secondary - Determine overall progression-free survival patient treat regimen . - Determine toxicity regimen patient . - Determine long-term effect regimen patient . - Determine predictive value fludeoxyglucose F 18 positron emission tomography ( FDG-PET ) , diffusion-weighted MRI , magnetic resonance spectroscopy evaluation treatment response patient treat regimen . OUTLINE : Patients stratify accord resectability primary tumor ( recurrent , refractory , high-risk disease v unresectable primary tumor ) . - Mobilization collection autologous peripheral blood stem cell ( PBSCs ) * : Patients receive ifosfamide IV daily 5 day follow filgrastim ( G-CSF ) subcutaneously daily . Patients undergo leukapheresis collection autologous PBSCs ≥ 2 x 10^6 CD34 ( cluster differentiation 34 ) -positive cells/kg collect . NOTE : *Patients undergo PBSC collection study entry proceed high-dose samarium Sm 153 lexidronam pentasodium ( 153Sm-EDTMP ) infusion without mobilization collection autologous PBSCs . - 153Sm-EDTMP infusion : Patients receive trace dose ^153Sm-EDTMP** IV 1-2 minute undergo bone scan 4 , 24 , 48-72 hour later . Six week later , patient receive high-dose ^153Sm-EDTMP IV 1-2 minute undergo repeat bone scan 4 , 24 , 48-72 hour later . NOTE : **Patients may receive trace dose protocol JHOC ( Johns Hopkins Oncology Center ) -J0094 . - Autologous peripheral blood stem cell transplantation ( PBSCT ) : Between 12-14 day administration high-dose ^153Sm-EDTMP , patient undergo autologous PBSCT . Beginning 2 day later , patient receive G-CSF IV daily . - External-beam radiotherapy : Patients undergo external-beam radiotherapy sit bulky disease . - Surgery : Some patient may also undergo surgical resection residual disease . After completion study treatment , patient follow periodically 3 year . PROJECTED ACCRUAL : A total 54 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Samarium ethylenediaminetetramethylenephosphonate</mesh_term>
	<criteria>Inclusion Diagnosis osteosarcoma Highrisk disease , meet 1 follow criterion : Recurrent disease Refractory conventional therapy Newly diagnose metastatic disease ≥ 4 pulmonary nodule multiple bone lesion Unresectable primary tumor Prior intralesional resection allow Measurable disease technetium Tc 99m diphosphonate bone scan Refractory standard therapy highly unlikely respond conventional treatment Performance status Karnofsky 60100 % Life expectancy 8 week Absolute neutrophil count &gt; 500/mm^3 Platelet count &gt; 50,000/mm^3 Creatinine clearance &gt; 70 mL/min OR * Radioisotope glomerular filtration rate normal Recovered prior chemotherapy Exclusion Pregnant nursing Positive pregnancy test female childbearing potential Fertile patient agree use effective contraception Prior radiotherapy site currently active disease Concurrent enrollment protocol JHOCJ0094 allow</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>localize osteosarcoma</keyword>
</DOC>